Back to news archive
Image for Gradientech presents QuickMIC® clinical study results
News 2022-05-17

Gradientech presents QuickMIC® clinical study results

Based on more than 3,800 drug-bug combinations and a total of 473 common sepsis-causing bacterial strains, including 64 patient samples the QuickMIC® study result showed an overall Essential Agreement (EA) of 94,7 %, an overall Categorical Agreement (CA) of 94,7 % and an impressive reproducibility between the study sites of 99.1%. Average time to result for all drug-bug combinations was just below 3 hours and 20 minutes.

Link to press-release

Gradientech is an ISO13485 certified company since 2017


Gradientech AB
Uppsala Science Park
SE-751 83 Uppsala

About Gradientech

Gradientech develops, manufactures and sells innovative microfluidic products for high-quality analysis of the behavior of cells and organisms in response to gradients of biomolecules. Our aim is to pioneer life science and healthcare.

Copyright © 2024 Gradientech. All rights reserved. Gradientech, QuickMIC and CellDirector are registered trademarks or trademarks of Gradientech AB.

Next-generation antimicrobial susceptibility testing

Take a look at our E-book